![](https://www.med.unc.edu/tarc/wp-content/uploads/sites/802/2021/02/Rumey-Ishizawar-mv2-238x300.jpg)
The study evaluated whether pre-existing RA was associated with a higher mortality and risk for immune-related adverse events with ICI use.
Joining Dr. Ishizawar in conducting this research were UNC colleagues; Dr. Amanda Lusa, Dr. Todd Schwartz, Carolina Alvarez, and Shruti Saxena Beem.
Learn more about the study findings via this summary in Rheumatology Advisor.